Journal of Surgery Concepts & Practice >

2021 , Vol. 26 >Issue 06: 564 - 567

DOI: https://doi.org/10.16139/j.1007-9610.2021.06.021

Review

Progress in study on apatinib in treatment of both radioactive iodine refractory and more aggressive thyroid carcinoma

Expand

Received date: 2021-02-19

  Online published: 2022-07-27

Fold

Cite this article

ZHAN Ling, QIU Weihua . Progress in study on apatinib in treatment of both radioactive iodine refractory and more aggressive thyroid carcinoma[J]. Journal of Surgery Concepts & Practice, 2021 , 26(06) : 564 -567 . DOI: 10.16139/j.1007-9610.2021.06.021

References

[1] Jin Y, van Nostrand D, Cheng L, et al. Radioiodine refractory differentiated thyroid cancer[J]. Crit Rev Oncol Hematol, 2018, 125:111-120.
[2] Cai S, Deng H, Chen Y, et al. Treatment of medullary thyroid carcinoma with apatinib: a case report and literature review[J]. Medicine (Baltimore), 2017, 96(50):e8704.
[3] Cheng L, Jiao Q, Jin Y, et al. Initial therapy of advanced anaplastic thyroid cancer via targeting VEGFR-2: a case report[J]. Onco Targets Ther, 2019, 12:10495-10500.
[4] Ibrahimpasic T, Ghossein R, Shah JP, et al. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects[J]. Thyroid, 2019, 29(3):311-321.
[5] Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers[J]. J Clin Endocrinol Metab, 2009, 94(5):1493-1499.
[6] Guleng B, Tateishi K, Ohta M, et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner[J]. Cancer Res, 2005, 65(13):5864-5871.
[7] Klein M, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma[J]. J Endocrinol, 1999, 161(1):41-49.
[8] Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940):319-328.
[9] Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7):621-630.
[10] Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase Ⅱtrial[J]. J Clin Oncol, 2013, 31(26):3219-3225.
[11] Xiao J, Liang J, Zhang W, et al. Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies[J]. Exp Ther Med, 2020, 20(3):1961-1966.
[12] Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers[J]. Drugs, 2018, 78(7):747-758.
[13] Zhou Y, Zhang W, Tang F, et al. A case report of apatinib in treating osteosarcoma with pulmonary metastases[J]. Medicine (Baltimore), 2017, 96(15):e6578.
[14] Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱtrial[J]. Clin Cancer Res, 2021, 27(4):1003-1011.
[15] Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase Ⅲtrial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13):1448-1454.
[16] Zhang S. Problematic analysis and inadequate toxicity data in phase Ⅲapatinib trial in gastric cancer[J]. J Clin Oncol, 2016, 34(31):3821.
[17] Hu X, Cao J, Hu W, et al. Multicenter phase Ⅱstudy of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14:820.
[18] Wu F, Zhang S, Xiong A, et al. A phase Ⅱclinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer[J]. Clin Lung Cancer, 2018, 19(6):e831-e842.
[19] Zhang Y, Deng X, Ding Z, et al. Preoperative neoadjuvant targeted therapy with apatinib for inoperable diffe-rentiated thyroid cancer: a case report[J]. Medicine (Baltimore), 2021, 100(12):e25191.
[20] Lin Y, Wang C, Gao W, et al. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer[J]. Oncotarget, 2017, 8(26):42252-42261.
[21] Chen K, Gao Y, Shi F, et al. Apatinib-treated advanced medullary thyroid carcinoma: a case report[J]. Onco Targets Ther, 2018, 11:459-463.
[22] Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Sta-ging System for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?[J]. Thyroid, 2017, 27(6):751-756.
[23] Sugitani I, Miyauchi A, Sugino K, et al. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients[J]. World J Surg, 2012, 36(6):1247-1254.
[24] De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004, 60(4):1137-1143.
[25] Niu Y, Ding Z, Deng X, et al. A novel multimodal therapy for anaplastic thyroid carcinoma: 125I seed implantation plus apatinib after surgery[J]. Front Endocrinol (Lausanne), 2020, 11:207.
[26] Chen W, Li Z, Zheng Z, et al. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: a single-center retrospective study[J]. Cancer Med, 2020, 9(16):5899-5907.
[27] Lin YS, Zhang X, Wang C, et al. Long-term results of phase Ⅱtrial of apatinib for progressive radioiodine refractory differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2021, 106(8):e3027-e3036.
[28] Zhang X, Wang C, Lin Y. Pilot dose comparison of apatinib in Chinese patients with progressive radioiodine-refractory differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2018, 103(10):3640-3646.
[29] Jin Z, Cheng X, Feng H, et al. Apatinib inhibits angiogenesis via suppressing Akt/GSK3β/ANG signaling pathway in anaplastic thyroid cancer[J]. Cell Physiol Biochem, 2017, 44(4):1471-1484.
[30] Feng H, Cheng X, Kuang J, et al. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer[J]. Cell Death Dis, 2018, 9(10):1030.
[31] Meng X, Wang H, Zhao J, et al. Apatinib inhibits cell proliferation and induces autophagy in human papillary thyroid carcinoma via the PI3K/Akt/mTOR signaling pathway[J]. Front Oncol, 2020, 10:217.
[32] Peng QX, Han YW, Zhang YL, et al. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma[J]. Oncotarget, 2017, 8(32):52813-52822.
[33] Liu S, Wu F, Zhang Y, et al. Apatinib combined with radiotherapy enhances antitumor effects in an in vivo nasopharyngeal carcinoma model[J]. Cancer Control, 2020, 27(1):1073274820922553.
[34] Li F, Zhu T, Cao B, et al. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance[J]. Eur J Cancer, 2017, 84:184-192.
[35] Hu Y, Zhou N, Wang R. Apatinib strengthens the anti-tumor effect of cisplatin in thyroid carcinoma through downregulating VEGFR2[J]. J BUON, 2021, 26(2):613-619.
[36] Tong XZ, Wang F, Liang S, et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells[J]. Biochem Pharmacol, 2012, 83(5):586-597.
[37] Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters[J]. Cancer Res, 2010, 70(20):7981-7991.
Options
Outlines

/

〈 〉